Top

Published in:

01-12-2021 | Coronavirus | COVID-19

SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature

Authors: Lorenzo Saraceno, Emanuela Laura Susani, Maria Raffaella Marazzi, Maria Cristina Moioli, Elio Clemente Agostoni, Alessandra Protti

Published in: Neurological Sciences | Issue 12/2021

Abstract

Literature data reporting SARS-CoV-2 infection in multiple sclerosis (MS) patients recently treated with immunodepleting agents as cladribine and alemtuzumab are very limited. The relationship between iatrogenic immunodeficiency and risk related to SARS-CoV-2 infection and its severe complications is still not clear. Cautiously, the start of immunosuppressant drugs as alemtuzumab and cladribine during the current COVID-19 pandemic is not recommended unless treatment benefits significantly outweigh potential risks. We report the case of a 30-year-old female MS patient infected by SARS-CoV-2 virus 4 months after alemtuzumab II cycle, while she was still leukopenic and lymphopenic. She had no complications and also presented milder COVID-related signs and symptoms as compared to her coinfected relatives (father, mother and her partner). Anti-S1 and S2 SARS-CoV-2 antibodies, tested 1 month and a half after the infection, resulted positive. We review all cases reported in literature of SARS-CoV-2 infection in MS patients treated with alemtuzumab. None of them had complications or severe disease.

Zhou F, Yu T, Du R et al (2020) Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062. https://doi.org/10.1016/S0140-6736(20)30566-3CrossRefPubMedPubMedCentral

Giovannoni G, Hawkes C, Lechner-Scott J et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073. https://doi.org/10.1016/j.msard.2020.102073CrossRefPubMedPubMedCentral

Fernández-Díaz E, Gracia-Gil J, García-García JG et al (2020) COVID-19 and multiple sclerosis: a description of two cases on alemtuzumab. Mult Scler Relat Disord 45:102402. https://doi.org/10.1016/j.msard.2020.102402CrossRefPubMedPubMedCentral

Carandini T, Pietroboni AM, Sacchi et al (2020) Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: a mild uncomplicated infection despite intense immunosuppression. Mult Scler:1352458520926459. https://doi.org/10.1177/1352458520926459

Guevara C, Villa E, Cifuentes M, Naves R, Grazia J (2020) Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab. Mult Scler Relat 44:102314. https://doi.org/10.1016/j.msard.2020.102314CrossRef

Fiorella C, Lorna G et al (2020) COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: insight to the immune response after COVID. Multiple Sclerosis and Related Disorders 46:102447. https://doi.org/10.1016/j.msard.2020.102447CrossRefPubMedPubMedCentral

Matías-Guiu J, Montero-Escribano P, Pytel V, Porta-Etessam J, Matias-Guiu JA (2020) Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab. Mult Scler Related Disorders 44:102297. https://doi.org/10.1016/j.msard.2020.102297CrossRef

Sormani MP, De Rossi N, Schiavetti I et al (2021) Disease-modifying therapies and coronavirus disease 2019 severity in multiple sclerosis. Ann Neurol. https://doi.org/10.1002/ana.26028

Iovino A, Olivieri N, Aruta F, Giaquinto E, Ruggiero L, Spina E, Tozza S, Manganelli F, Iodice R (2021) Alemtuzumab in Covid era. Mult Scler Related Disorders 51:102908. https://doi.org/10.1016/j.msard.2021.102908CrossRef

10.

Giovannoni G, Boster AL, Berkovich R et al (2021) Cases of COVID-19 in Alemtuzumab-treated patients with MS: pharmacovigilance report. American Academy of Neurology

11.

Dalla Costa G, Leocani L, Montalban X, Guerrero AI, Sørensen PS, Magyari M, Dobson RJB, Cummins N, Narayan VA, Hotopf M, Comi G, on behalf of the RADAR-CNS consortium (2020) Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci 41(7):1647–1650. https://doi.org/10.1007/s10072-020-04519-xCrossRefPubMedPubMedCentral

12.

Louapre C, Collongues N, Stankoff B, Giannesini C, Papeix C, Bensa C, Deschamps R, Créange A, Wahab A, Pelletier J, Heinzlef O, Labauge P, Guilloton L, Ahle G, Goudot M, Bigaut K, Laplaud DA, Vukusic S, Lubetzki C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 1(77(9)):1079–1088. https://doi.org/10.1001/jamaneurol.2020.2581CrossRef

13.

Reder AT, Centonze D, Naylor ML, Nagpal A, Rajbhandari R, Altincatal A, Kim M, Berdofe A, Radhakrishnan M, Jung E, Sandrock AW, Smirnakis K, Popescu C, de Moor C (2021) COVID-19 in patients with multiple sclerosis: associations with disease-modifying therapies. CNS Drugs 35(3):317–330. https://doi.org/10.1007/s40263-021-00804-1CrossRefPubMedPubMedCentral

14.

Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord.43:102195. doi: https://doi.org/10.1016/j.msard.2020.102195, 43, 102195

15.

Biying H, Shaoying H, Lianghong Y (2021) The cytokine storm and. COVID-19- J Med Virol 93(1):250–256. https://doi.org/10.1002/jmv.26232CrossRef

Title: SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature
Authors: Lorenzo Saraceno
Emanuela Laura Susani
Maria Raffaella Marazzi
Maria Cristina Moioli
Elio Clemente Agostoni
Alessandra Protti
Publication date: 01-12-2021
Publisher: Springer International Publishing
Keywords: Coronavirus
Multiple Sclerosis
Myalgie
Cough
Myalgia
SARS-CoV-2
Cough
Cough
Alemtuzumab
Cladribine
Alemtuzumab
Published in: Neurological Sciences / Issue 12/2021
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-021-05567-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

SARS-CoV-2 infection after alemtuzumab in a multiple sclerosis patient: milder disease symptoms in comparison with coinfected relatives: a case report and review of the literature

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 12/2021

Abnormal neurological pupil index is associated with malignant cerebral edema after mechanical thrombectomy in large vessel occlusion patients

“No man is an island”—unique pattern of anhidrosis with islands of preserved sweat in Ross syndrome

Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease

Comparative study between idiopathic and non-idiopathic dystonia: a prospective observational study

Cognitive impairment in young COVID-19 patients: the tip of the iceberg?

Cognitive impairment in multiple sclerosis: diagnosis and monitoring